NeuroSense Therapeutics (NeuroSense Therapeutics) Cash-to-Debt : 18.59 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NeuroSense Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 18.59.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NeuroSense Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for NeuroSense Therapeutics's Cash-to-Debt or its related term are showing as below:

NRSNW' s Cash-to-Debt Range Over the Past 10 Years
Min: 18.59 Med: No Debt Max: No Debt
Current: 18.59

During the past 5 years, NeuroSense Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 18.59. And the median was No Debt.

NRSNW's Cash-to-Debt is ranked better than
64.08% of 1523 companies
in the Biotechnology industry
Industry Median: 6.23 vs NRSNW: 18.59

NeuroSense Therapeutics Cash-to-Debt Historical Data

The historical data trend for NeuroSense Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NeuroSense Therapeutics Cash-to-Debt Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

33.60

18.59

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										33.60	35.02	68.16	56.66	18.59

Competitive Comparison of NeuroSense Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, NeuroSense Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Cash-to-Debt falls into.

NeuroSense Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NeuroSense Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.64	/	(0.069	+	0.073)
	=	18.59

NeuroSense Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.64	/	(0.069	+	0.073)
	=	18.59

NeuroSense Therapeutics (NAS:NRSNW) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NeuroSense Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NRSN:USA

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.